Navigation Links
Pharsight Signs Two New DMX(R) License Customers
Date:4/2/2008

e drug development decision-making for promising therapies in their pipelines," said Shawn O'Connor, president, chief executive officer and chairman of Pharsight. "We believe DMX can enhance the cost and efficiency benefits of using modeling and simulation by helping clinical development project teams make decisions earlier and with greater confidence."

"DMX's intuitive visualization of model-based product profiles enables drug development teams to interact with complex information, particularly when a new drug faces tough competition," continued Mr. O'Connor. "We continue to see leading drug development organizations incorporate quantitative modeling and simulation, as advocated by the Food and Drug Administration in its Critical Path Initiative, into their decision-making processes."

About DMX

DMX is a software visualization and communication tool to explore model-based results of a compound's product profile. Through the DMX interface the development team can address key strategic development questions by comparing probabilistic outcomes for different endpoints, treatment strategies, and patient populations against competing products. DMX results are presented as a series of plots and tables that can be quickly updated based on pre-simulated models of clinical effect. Results are accessible from networked desktop or laptop computers for individual exploration, interactive team discussion, and communication of development strategies and program alternatives with senior decision-makers. Pharsight believes that DMX will help increase the usage of quantitative decision-making in the drug development process.

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk o
'/>"/>

SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharsight Achieves First License Sale for Public-Source Database
2. Pharsight to Present at ROeS Seminar in Bern, Switzerland on September 10 & 11, 2007
3. Pharsight Expands Strategic Consulting Services Team
4. Pharsight Hosts Fourth Annual PKS User Group Meeting
5. Pharsight Invited to Present on Winning Strategies for R&D Productivity at New York Pharma Forum on October 15, 2007
6. Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
7. Pharsight Announces 1-For-3 Reverse Stock Split
8. Pharsight Signs Third WinNonlin(R) AutoPilot(TM) Customer
9. Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone
10. Pharsight Announces Fiscal Third Quarter 2008 Earnings Release Date and Conference Call
11. Pharsight Achieves $7.4 Million in Quarterly Revenue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 21, 2015  CytRx Corporation (NASDAQ: CYTR ... in oncology, today announced positive updated results from ... for the treatment of unresectable glioblastoma multiforme (GBM), ... multisite trial is designed to investigate the preliminary ... tumors have progressed following prior treatment with surgery, ...
(Date:5/21/2015)... - RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: ... on the development of autologous cell therapies, announced ... Society for Cellular Therapy (ISCT) on RepliCel,s autologous ... a Phase 1/2 clinical trial.  The presentation, taking ... PM to 7:00 PM local time, will review ...
(Date:5/20/2015)... , May 20, 2015 ... presented preliminary data demonstrating the ability of the ... fibrosis (IPF) from other interstitial lung diseases (ILDs) ... the classifier,s potential to help thousands of patients ... ambiguity in IPF diagnosis – a frequent challenge ...
(Date:5/20/2015)... , May 19, 2015 Research and Markets ... of the "Global Cell Therapy Market Outlook 2020 ... of cell therapy in tissue and regenerative medicine is ... no other options which could help in the growth ... this segment but they are unable to form new ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
... Pioneering Field, BETHESDA, Md., Sept. 10 ... an ownership interest in,ClinResearch GmbH, a global leader ... clinical trials. Headquartered in Cologne, Germany,with more than ... programs over the past seven years. ClinResearch,s co-founder,Reinhard ...
... a broad array, of biometric enrollment ... Sept. 10 Aware, Inc. (Nasdaq:,AWRE), a global ... long history of success in providing high-quality,innovative software ... comprehensive suite of products in their booth (#501) ...
... September 13 to Discuss Phase 1 Trial and Other Major ... ... CA, Sept. 10 /PRNewswire-FirstCall/ - Nventa,Biopharmaceuticals Corporation (TSX:NVN) today announced the ... tolerability of new,HspE7 (HspE7 dosed with an adjuvant) in 24 patients ...
Cached Biology Technology:United BioSource Acquires Interest in Leading Adaptive Design Technology Service Provider 2Aware Celebrates Fifteen Years of Innovation and Leadership in the Biometrics Industry 2Aware Celebrates Fifteen Years of Innovation and Leadership in the Biometrics Industry 3Aware Celebrates Fifteen Years of Innovation and Leadership in the Biometrics Industry 4Aware Celebrates Fifteen Years of Innovation and Leadership in the Biometrics Industry 5Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial 2Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial 3Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial 4Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial 5Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial 6
(Date:5/7/2015)... 7, 2015 Fingerprint Cards ... and FPC1035, FPC,s smallest touch fingerprint sensors to ... considered for integration on the backside of the ... increased possibilities to integrate touch fingerprint sensors in ... improves possibilities for module manufacturers to customize the ...
(Date:4/27/2015)...  For more than four decades, AUVSI,s Unmanned ... premier worldwide event for the unmanned land, sea, and ... for any local, national, or trade news organization interested ... and current applications of unmanned technologies. The conference will ... billion industry, and how it will soon impact the ...
(Date:4/21/2015)... 21, 2015 High crime ... are boosting access control systems market in ... a recently published report by TechSci Research " Saudi ... access control systems market in Saudi Arabia ... 2020.The access control systems market in the Kingdom is ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3
... retreat from equatorial seas and oceans as the Earth continues ... Working on clues in the fossil coral record from ... the last two ice ages about 125,000 years ago, the ... near the equator. "When the climate warmed rapidly during ...
... researchers have revealed the secrets of survival of an ... desert, and suggest that recent violence in Mali may ... study, to appear in January,s edition of Biological ... System (GPS) collars. Its findings advance conservation efforts for ...
... 12, 2012 Cell aging, or cellular senescence, has ... tumor development. Activated oncogenes are able to induce senescence, ... could play a key role in future cancer therapy. ... the regulation of OIS. This study is published online ...
Cached Biology News:Scary news for corals -- from the Ice Age 2Violence in Mali threatening survival of endangered elephants 2Previously unknown mechanism identified in oncogene-induced senescence 2
MOUSE ANTI PORCINE SLA 1:FITC Immunogen: Porcine peripheral blood mononuclear cells....
An excellent carbonyl-reactive FRET quencher paired with Trp or Tyr. Minimum Purity: 95%. Abs(max): ~350 nm; Em(max): none. Solvent System:DMSO or DMF....
EDG-6 (1)...
Complexin-1/2 (FL-134)...
Biology Products: